ERBB2 and colonic neoplasm: Our study demonstrates that neoadjuvant chemotherapy combined with trastuzumab and pertuzumab is an effective treatment strategy for locally advanced HER2-positive colon cancer patients, indicating the potential of HER2 targeting in neoadjuvant therapy and highlighting the importance of assessing HER2 status in all colorectal cancer patients.